Drug2nd line
Dapsone
Anti-neutrophilic; inhibits myeloperoxidase and neutrophil chemotaxis
- Response rate
- Effective for cutaneous symptoms in most cases
- Onset
- Days–weeks
- Route
- Oral 25-150 mg daily
- Line
- 2nd
- IgM effect
- Minimal complement effect
- Evidence level
- amber
Evidence summary
Anti-neutrophilic agent effective for cutaneous manifestations of HUVS. Eiser et al. reported sustained remission in a patient resistant to cyclophosphamide and corticosteroids. May be the preferred agent for cutaneous-predominant disease. Requires G6PD testing before initiation.
Drug identifiers
| DrugBank | DB00250 ↗ |
| ATC Code | J04BA02 |